PANews reported on September 2nd, according to GlobeNewswire, that biopharmaceutical company Propanc Biopharma (Nasdaq: PPCB) announced plans to acquire $100 million in Ethereum over the next 12 months. The company stated that this move aims to increase its cryptocurrency asset allocation and accelerate drug development and asset acquisitions. Propanc cited Ethereum's support for smart contracts and decentralized applications, its superior energy efficiency compared to Bitcoin, and its advantages in liquidity and global accessibility in asset tokenization. The company will primarily use the funds to hold Ethereum, with a portion allocated for drug development and IP acquisition.PANews reported on September 2nd, according to GlobeNewswire, that biopharmaceutical company Propanc Biopharma (Nasdaq: PPCB) announced plans to acquire $100 million in Ethereum over the next 12 months. The company stated that this move aims to increase its cryptocurrency asset allocation and accelerate drug development and asset acquisitions. Propanc cited Ethereum's support for smart contracts and decentralized applications, its superior energy efficiency compared to Bitcoin, and its advantages in liquidity and global accessibility in asset tokenization. The company will primarily use the funds to hold Ethereum, with a portion allocated for drug development and IP acquisition.
Propanc Biopharma to acquire $100 million in Ethereum to diversify its assets
PANews reported on September 2nd, according to GlobeNewswire, that biopharmaceutical company Propanc Biopharma (Nasdaq: PPCB) announced plans to acquire $100 million in Ethereum over the next 12 months. The company stated that this move aims to increase its cryptocurrency asset allocation and accelerate drug development and asset acquisitions. Propanc cited Ethereum's support for smart contracts and decentralized applications, its superior energy efficiency compared to Bitcoin, and its advantages in liquidity and global accessibility in asset tokenization. The company will primarily use the funds to hold Ethereum, with a portion allocated for drug development and IP acquisition.
Market Opportunity
Movement Price(MOVE)
$0.03727
$0.03727$0.03727
USD
Movement (MOVE) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.
You May Also Like
XRP Crowned South Korea’s Most-Traded Crypto of 2025
XRP Surpasses Bitcoin and Ethereum as South Korea’s Most Traded Crypto in 2025According to renowned market analyst X Finance Bull, XRP dominated South Korea’s crypto
Share
Coinstats2026/01/16 16:54
SBI Ripple Asia signs MOU with Tobu Top Tours to develop tokenized payments
SBI Ripple Asia is partnering with Tobu Top Tours to build closed-loop payment ecosystems. The venture will mint unique tokens for destinations and brands, tethering spending power to digital fan engagement and localized travel experiences. According to an announcement on…
Share
Crypto.news2025/09/30 21:31
Why Bitcoin’s $100K “Resistance” Is Artificial, Not Technical
$1.2B in gamma exposure mechanically suppresses Bitcoin rallies through automated dealer hedging strategies. Call walls at $100K and put floors at $90K trap Bitcoin
Share
LiveBitcoinNews2026/01/16 17:00